Reversing Aging
to Treat Disease

About Us

At Fountain Therapeutics, we have combined the expertise of leaders in aging research and computation to build a pipeline of therapeutics aimed at reversing cellular aging. Our mission is to decouple aging from disease and significantly extend human health span.

Our AI-driven platform extracts previously hidden cellular features to measure aging with remarkable precision. This has enabled us to generate unprecedented insights into the cellular aging process. We have united science, medicine and engineering to turn these insights and technologies into a powerful drug discovery and development engine for the treatment of age-related diseases.

Aging and Health

Aging is the predominant challenge to our health and quality of life.

Cellular aging shares similar biological pathways with many other physiological processes in our body. This provides us with an opportunity for therapeutic intervention to ameliorate many diseases of aging. At Fountain, we are dedicated to developing the first therapeutics to target and reverse aging processes as a new way to treat the many diseases that aging brings.

Fountain Team

Fountain is comprised of an exceptional team of scientists, engineers, physicians, drug hunters and developers, entrepreneurs and visionaries who see the path to a healthier future. Our team members’ unique experiences and extensive expertise in aging research and medicine are merged to achieve a universal goal of building a new way forward to treat age-related health conditions.


William L. Greene, M.D.

William L. Greene, M.D.

Chief Executive Officer

View Bio
Thomas Rando

Thomas Rando, M.D., Ph.D.

Co-Founder, Chair of the
Board of Directors

View Bio
Joe Rodgers

Joseph Rodgers, Ph.D.

Director of Biology

View Bio
Tom Cheung

Tom Cheung, Ph.D.


View Bio

Our Investors

Recent News

Fountain Therapeutics Announces $15 Million Series A-2 Financing

Fountain Therapeutics to Present at 2nd Annual LifeSci Partners Private Company Summer Symposium

Fountain Therapeutics Appoints William L. Greene, M.D. Chief Executive Officer

Scrip Asks…What Does 2021 Hold For Biopharma? Part 4: Technology And Disease

Biopharma Executive Perspectives on 2021

A year in Longevity: science perspectives

View From The Inside: What’s Shaping Biopharma In 2021 And Beyond?

HQ Move Fuels Fountain’s AI Drug Discovery Machine

SMA, NMOSD and Aging – From Few to EveryoneOctober 14, 2020 Radio show

Fountain Therapeutics Moves Corporate Headquarters to Lilly Gateway Labs in South San Francisco

Healthy aging – it’s still all about diet and exercise. For now

Intervening in the Aging Process to Treat Age-Associated Diseases with John Dimos Fountain Therapeutics

Targeting Diseases of Aging at a Cellular Level

Fountain Therapeutics: an AI-based platform to reverse cellular aging

Hiring During COVID-19: Business as Usual in the New Normal

Biotech Startups Look to Test Employees for Covid-19 in Bid to Get Back to Normal

Fountain’s ‘hypothesis-free’ approach to Longevity AI

Fountain Therapeutics Closes $6 Million Series A-1 Financing

Fountain fires up aging drugs platform with new $6M financing

Four medical school professors elected to American Academy of Arts and Sciences

Join Our Team

We are looking for fellow scientists, engineers and entrepreneurs who share our mission of building a new path forward to improve the length of quality life.

Interested in becoming part of our growing team passionate for innovation, technology and aging research?
Reach out to us:

Contact Us

We are here to answer any questions you may have about Fountain including our technology and business objectives. Looking to invest in us or exploring a partnering opportunity? Reach out to us:

Scroll to Top